Pharminent

Theravance and Mylan’s COPD treatment shows benefits in phase 3 trials

A drug that is being developed by Theravance Biopharma and Mylan has shown promise in two phase 3 efficacy studies treating patients with chronic obstructive pulmonary disease. http://clinicaltrials.pharmaceutical-business-review.com/news/theravance-and-mylans-copd-treatment-shows-benefits-in-phase-3-trials-211016-5039060

Filed under: COPD